农业百科

Its predecessor, Redalpine Capital VII, closed at $200 million in 2024. The new fund is therefore 25% larger. This development contrasts with the overall decline in fundraising in German-speaking countries. According to PitchBook data, 83 venture capital funds closed in 2022, raising a combined €6.2 billion. In the first nine months of 2025, only 21 funds closed, raising a total of €2 billion. The median time between a fund’s launch and final closing most recently stood at 26 months.

Why it matters: According to Zealand Pharma, the November 9 SYNCHRONIZE-CVOT results complete the registrational Phase 3 program intended to support Boehringer’s planned regulatory submissions for obesity. Boehringer describes it as “the first and only global cardiovascular safety trial of a glucagon/GLP-1 dual agonist to date.”

Why it matters: Approved disease-modifying treatments for Alzheimer’s, including Leqembi and Kisunla, target amyloid plaques in the brain. Oyster is pursuing another hallmark of the disease: abnormal accumulations of tau inside neurons, which are associated with neuronal damage and cognitive decline.

Why it matters: Both trials tested ways to prevent heart attacks and strokes beyond lowering LDL cholesterol, one by suppressing inflammation and the other by reducing lipoprotein(a) (Lp(a)) a largely inherited cardiovascular risk factor elevated in approximately one in five people. Their failures challenge two closely watched drug-development strategies but do not establish conclusively that either biological target is ineffective.

Windward targets $204 million from IPO and Sanofi placement: The Swiss biotech plans to offer approximately 10.3 million shares at $16–$18 each. At the midpoint, the offering and a separate $50 million Sanofi investment would generate approximately $203.8 million in combined net proceeds. Founded in 2024 and publicly launched in January 2025 with a $200 million Series A, Windward is pursuing Nasdaq less than two years after launch, following its $165 million Series B. Its model combines experienced leadership — CEO Luca Santarelli previously built Therachon and VectivBio — with clinical-stage medicines licensed from China. The proceeds would support respiratory and dermatology studies of WIN378, an anti-TSLP antibody, and WIN027, which targets TSLP and IL-13. The IPO remains pending.

Why it matters: Immunotherapies such as checkpoint inhibitors have transformed cancer treatment, but many patients do not respond. One reason is the tumor microenvironment: a dense network of proteins and other molecules surrounding cancer cells that can prevent immune cells from reaching their targets.

Why it matters: The early result exceeds the 45% two-year survival seen with Kimmtrak alone in its landmark Phase 3 trial, raising the possibility that attacking two tumor targets could improve on the existing treatment for this rare and aggressive eye cancer.

Regulatory consultancy Arcus Compliance has launched a SaaS (software as a service) tool to streamline monitoring and adherence to UK and European regulatory requirements. Mavryx Assistant is designed to support founders, start-ups, and brands in the beauty industry. 

The Estée Lauder Companies (ELC) has debuted a longevity-focused scientific innovation platform, Mastering Skin Longevity. The platform is touted to advance the beauty giant’s ingredient innovations, technologies, formulations, and future product development.